BridgeBio Pharma
BBIO · Nasdaq · United States
Share price · BBIO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026+6.0%
- 9 Jul 2026+15.1%
Nothing announced by BBIO that day or the session before.
- 10 Mar 2026+13.2%
Nothing announced by BBIO that day or the session before.
- 19 Feb 2026-4.3%
Nothing announced by BBIO that day or the session before.
- 12 Feb 2026+3.7%
Nothing announced by BBIO that day or the session before.
- 9 Feb 2026+6.2%
Nothing announced by BBIO that day or the session before.
- 5 Feb 2026-15.2%
Nothing announced by BBIO that day or the session before.
- 9 Jan 2026+4.6%
Nothing announced by BBIO that day or the session before.
Share of unusual movement by asset
For each asset, the share of BBIO's own-move activity since 11 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 5% |
| Sessions with no dated event | — | 95% |
No dated announcements about its assets since 11 Nov 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Acoramidis(Attruby) | Approved | Transthyretin (TTR)Small molecule | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Cardiomyopathy |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
April 2028 (1)
What to watch
2031 (1)
October 2031 (1)
What to watch
2037 (1)
November 2037 (1)
What to watch
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $353M | $144M | $1.5B+ $5.5M short-term inv. | $57M-$44M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $244M | $149M | $678M+ $42M short-term inv. | $152M-$71M operating cash flow | report ↗ |
| 2026-Q1 | $195M | $127M | $880M+ $60M short-term inv. | $164M-$197M operating cash flow | report ↗ |
| 2025-Q3 | $121M | $113M | $643M+ $3.0M short-term inv. | $183M-$110M operating cash flow | report ↗ |
| 2025-Q2 | $111M | $111M | $749M+ $7.9M short-term inv. | $182M-$81M operating cash flow | report ↗ |
| 2025-Q1 | $117M | $111M | $541M | $167M-$199M operating cash flow | report ↗ |
| 2024-Q3 | $2.7M | $120M | $266M | $162M-$181M operating cash flow | report ↗ |
| 2024-Q2 | $2.2M | $115M | $408M+ $40M short-term inv. | $73M$75M operating cash flow | report ↗ |
| 2024-Q1 | $211M | $141M | $475M+ $44M short-term inv. | $35M-$220M operating cash flow | report ↗ |
| 2023-Q3 | $4.1M | $125M | $505M+ $0 short-term inv. | $177M-$145M operating cash flow | report ↗ |
| 2023-Q2 | $1.6M | $107M | $302M+ $31M short-term inv. | $158M-$113M operating cash flow | report ↗ |
| 2023-Q1 | $1.8M | $93M | $407M+ $34M short-term inv. | $140M-$144M operating cash flow | report ↗ |
| 2022-Q3 | $0.3M | $93M | $483M+ $75M short-term inv. | $137M-$135M operating cash flow | report ↗ |
| 2022-Q2 | $74M | $108M | $470M+ $218M short-term inv. | $9.9M-$30M operating cash flow | report ↗ |
| 2022-Q1 | $1.7M | $108M | $372M+ $262M short-term inv. | $196M-$161M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $502M | $452M | $570M+ $17M short-term inv. | $181M-$446M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $222M | $506M | $681M+ $0 short-term inv. | $134M-$521M operating cash flow | report ↗ |
| 2023-FY | $9.3M | $456M | $376M+ $0 short-term inv. | $161M-$528M operating cash flow | report ↗ |
| 2022-FY | $78M | $399M | $377M+ $52M short-term inv. | $120M-$419M operating cash flow | report ↗ |
| 2021-FY | $70M | $451M | $394M+ $394M short-term inv. | $141M-$498M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 129 sales ($84.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Kumar Neil · director, Chief Executive Officer | Option exercise | 33,544 | — | — | Form 4 |
| 2026-11-16 | Apuli Maricel · Chief Accounting Officer | Tax withholding | 4,714 | $77.36 | $365K | Form 4 |
| 2026-11-16 | Trimarchi Thomas · President and CFO | Tax withholding | 22,781 | $77.36 | $1.8M | Form 4 |
| 2026-11-16 | Kumar Neil · director, Chief Executive Officer | Option exercise | 19,599 | — | — | Form 4 |
| 2026-11-16 | Kumar Neil · director, Chief Executive Officer | Option exercise | 11,554 | — | — | Form 4 |
| 2026-11-16 | Kumar Neil · director, Chief Executive Officer | Option exercise | 6,519 | — | — | Form 4 |
| 2026-11-16 | Kumar Neil · director, Chief Executive Officer | Tax withholding | 36,236 | $77.36 | $2.8M | Form 4 |
| 2026-11-16 | Kumar Neil · director, Chief Executive Officer | Option exercise (derivative) | 33,544 | — | — | Form 4 |